Michelle Maria Aleida Kip
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Michelle Maria Aleida Kip has a total of 106 co-authors. Here are the top co-authors by number of shared publications:
- Maarten J. Ijzerman
Sir Peter MacCallum Department of Oncology, University of Melbourne, Australia; Cancer Health Services Research, University of Melbourne, Australia; Erasmus School of Health Policy & Management, Rotterdam, The Netherlands
13 shared publications - Hendrik Koffijberg
University of Twente
10 shared publications Ron Kusters
Department of Health Technology and Services Research, University of Twente, Technical Medical Center, Faculty of Behavioural, Management and Social Sciences, Enschede, the Netherlands
7 shared publications- Deborah A. Marshall
Department of Community Health Sciences, Cumming School of Medicine University of Calgary Calgary Alberta Canada
5 shared publications Nico Wulffraat
Department of Pediatric Rheumatology, Division of Paediatrics, University Medical Center Utrecht, Wilhelmina Children’s Hospital, Utrecht, The Netherlands
5 shared publications- Joost F. Swart
Department of Pediatric Immunology and Rheumatology Wilhelmina Children's Hospital/UMC Utrecht Utrecht the Netherlands
4 shared publications
Latest Publications
- Open Access
- 6 August 2026
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 21 (8) , e0354879
Early versus delayed trial without catheter in men with Acute urinary retention - Study Protocol for a dutch national randomized trial
Introduction: Acute urinary retention (AUR) is a burdensome urological emergency, often caused by benign prostatic obstruction. Standard management includes transurethral catheterization, alpha-blocker therapy, and a trial without catheter (TWOC) to assess spontaneous voiding. Despite the high incidence of AUR, the optimal catheter duration prior to TWOC remains uncertain. Evidence is limited, guideline recommendations are largely expert-based, and catheter duration varies widely in practice. Prolonged catheterization may increase morbidity and discomfort, whereas earlier removal may raise concerns regarding recurrent retention. Methods: RELIEF is a pragmatic, multicenter, randomized non-inferiority trial comparing TWOC on day 3 versus TWOC on day 14 in men with AUR. All participants undergo transurethral catheterization and receive alpha-blocker therapy prior to randomization. Primary outcome is TWOC success, defined as a voided volume ≥100 mL and post-void residual ≤200 mL. The primary analysis follows a per-protocol approach, with a complementary intention-to-treat analysis to confirm non-inferiority. Secondary outcomes include recurrent retention, catheter-related complications, patient-reported symptoms and quality of life, and cost-effectiveness from healthcare and societal perspectives over 18 months. In parallel, a qualitative substudy using semi-structured interviews with healthcare professionals aims to explore the determinants underlying current practice variation, as well as the perceived barriers and facilitators for the sustainable implementation of a standardized TWOC strategy in future clinical practice. Discussion: By comparing two catheterization intervals already applied in routine care and combining clinical, patient-reported, economic, and implementation outcomes, RELIEF is designed to generate directly applicable evidence on TWOC timing after AUR. The results are expected to support guideline refinement and improve consistency of care. Trial registration: WHO ICTRP primary registry, identifier NL-OMON57836. Registered on February 7, 2025.
- 6 August 2026
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 21 (8) , e0354879
Open AccessEarly versus delayed trial without catheter in men with Acute urinary retention - Study Protocol for a dutch national randomized trial
Introduction: Acute urinary retention (AUR) is a burdensome urological emergency, often caused by benign prostatic obstruction. Standard management includes transurethral catheterization, alpha-blocker therapy, and a trial without catheter (TWOC) to assess spontaneous voiding. Despite the high incidence of AUR, the optimal catheter duration prior to TWOC remains uncertain. Evidence is limited, guideline recommendations are largely expert-based, and catheter duration varies widely in practice. Prolonged catheterization may increase morbidity and discomfort, whereas earlier removal may raise concerns regarding recurrent retention. Methods: RELIEF is a pragmatic, multicenter, randomized non-inferiority trial comparing TWOC on day 3 versus TWOC on day 14 in men with AUR. All participants undergo transurethral catheterization and receive alpha-blocker therapy prior to randomization. Primary outcome is TWOC success, defined as a voided volume ≥100 mL and post-void residual ≤200 mL. The primary analysis follows a per-protocol approach, with a complementary intention-to-treat analysis to confirm non-inferiority. Secondary outcomes include recurrent retention, catheter-related complications, patient-reported symptoms and quality of life, and cost-effectiveness from healthcare and societal perspectives over 18 months. In parallel, a qualitative substudy using semi-structured interviews with healthcare professionals aims to explore the determinants underlying current practice variation, as well as the perceived barriers and facilitators for the sustainable implementation of a standardized TWOC strategy in future clinical practice. Discussion: By comparing two catheterization intervals already applied in routine care and combining clinical, patient-reported, economic, and implementation outcomes, RELIEF is designed to generate directly applicable evidence on TWOC timing after AUR. The results are expected to support guideline refinement and improve consistency of care. Trial registration: WHO ICTRP primary registry, identifier NL-OMON57836. Registered on February 7, 2025.
- Open Access
- 25 May 2026
- Published by Springer Nature in Cost Effectiveness and Resource Allocation
- Vol. 24 (1)
Exploring the cost-effectiveness of 3-D-guided versus traditional 2-D corrective osteotomy in patients with a distal radius malunion
Distal radius malunion is a frequent complication after a distal radius fracture, impairing function and quality of life. Corrective osteotomy using conven
- 25 May 2026
- Published by Springer Nature in Cost Effectiveness and Resource Allocation
- Vol. 24 (1)
Open AccessExploring the cost-effectiveness of 3-D-guided versus traditional 2-D corrective osteotomy in patients with a distal radius malunion
Distal radius malunion is a frequent complication after a distal radius fracture, impairing function and quality of life. Corrective osteotomy using conven
- Open Access
- 14 August 2025
- Published by Springer Nature in Netherlands Heart Journal
- Vol. 33 (10) , 307-312
Making a difference: describing and evaluating the impact of the Dutch CardioVascular Alliance
Introduction: In 2018, the Dutch CardioVascular Alliance (DCVA), a collaboration between 24 partners in the cardiovascular field, expressed the ambition to reduce the cardiovascular disease (CVD) burden in the Netherlands by 25% in 2030. This project aimed to evaluate the extent to which the activities within the DCVA contribute to a reduction in the burden defined as morbidity and mortality combined. Methods: The role and potential impact of the DCVA was assessed. Three assessments were conducted: 1) to determine the potential impact of consortia (n = 32) using a checklist; 2) to estimate the potential health benefit (quality-adjusted life years, (QALYs)) and cost savings from a snapshot of consortia (n = 4). Results: Most of the consortia focused on treatment (31%), followed by secondary prevention/monitoring (23%) and diagnosis (23%). Almost all consortia (n = 31) aim to reduce morbidity and two-thirds (n = 21) aim to reduce mortality. The four consortia evaluated were Check@Home, LoDoCo2, CONTRAST 2.0 and IMPRESS, with pathways in screening, treatment, treatment and diagnosis, respectively. The total estimated cumulative QALYs gained (from 2023 to 2030) were 1,694, 362, 2,783, and 3,655 respectively. Discussion: Although it is impossible to estimate the full impact of the DCVA itself, the presented checklist and analyses may increase awareness of the different DCVA activities, roles, and consortia. Existing HTA methods can support the exploration of the potential impact generated by each consortium within the DCVA. The current portfolio of DCVA consortia contributes extensively to the DCVA goal of reducing the CVD burden, provided there is effective support for the adoption and implementation of innovations.
- 14 August 2025
- Published by Springer Nature in Netherlands Heart Journal
- Vol. 33 (10) , 307-312
Open AccessMaking a difference: describing and evaluating the impact of the Dutch CardioVascular Alliance
Introduction: In 2018, the Dutch CardioVascular Alliance (DCVA), a collaboration between 24 partners in the cardiovascular field, expressed the ambition to reduce the cardiovascular disease (CVD) burden in the Netherlands by 25% in 2030. This project aimed to evaluate the extent to which the activities within the DCVA contribute to a reduction in the burden defined as morbidity and mortality combined. Methods: The role and potential impact of the DCVA was assessed. Three assessments were conducted: 1) to determine the potential impact of consortia (n = 32) using a checklist; 2) to estimate the potential health benefit (quality-adjusted life years, (QALYs)) and cost savings from a snapshot of consortia (n = 4). Results: Most of the consortia focused on treatment (31%), followed by secondary prevention/monitoring (23%) and diagnosis (23%). Almost all consortia (n = 31) aim to reduce morbidity and two-thirds (n = 21) aim to reduce mortality. The four consortia evaluated were Check@Home, LoDoCo2, CONTRAST 2.0 and IMPRESS, with pathways in screening, treatment, treatment and diagnosis, respectively. The total estimated cumulative QALYs gained (from 2023 to 2030) were 1,694, 362, 2,783, and 3,655 respectively. Discussion: Although it is impossible to estimate the full impact of the DCVA itself, the presented checklist and analyses may increase awareness of the different DCVA activities, roles, and consortia. Existing HTA methods can support the exploration of the potential impact generated by each consortium within the DCVA. The current portfolio of DCVA consortia contributes extensively to the DCVA goal of reducing the CVD burden, provided there is effective support for the adoption and implementation of innovations.
- Open Access
- 1 July 2025
- Published by SAGE Publications in MDM Policy & Practice
- Vol. 10 (2)
Development and Qualitative Evaluation of a Decision Support Tool for Withdrawal of Biologic Therapy in Nonsystemic Juvenile Idiopathic Arthritis
Introduction. Limited evidence guides pediatric rheumatologists on when to withdraw biologic therapy in children with juvenile idiopathic arthritis, resulting in wide variation in clinical practice. This study aimed to develop and evaluate a decision support tool (DST) based on expert opinion to support pediatric rheumatologists in making withdrawal decisions. Methods. A literature review, focus groups, interviews, and prior research informed the design of the prototype DST. Evaluation of the DST’s face validity, content validity, acceptance, and feasibility was conducted through user testing interviews and a survey among pediatric rheumatologists from the Netherlands and Canada. Findings were summarized using descriptive and qualitative content analyses. Results. The prototype DST requires input on relevant patient, disease, and treatment characteristics. Its primary output is the predicted likelihood of biologic therapy withdrawal. Pediatric rheumatologists can adjust the importance of characteristics and observe the resulting impact on withdrawal likelihood. Eleven pediatric rheumatologists participated in testing. Key themes identified included the need for 1) clear terminology to ensure consistent interpretation of model inputs, 2) concise instructions on how and when to adjust the relative importance of characteristics, and 3) practice rounds to build trust among pediatric rheumatologists in the DST’s output. Participants found the DST feasible for clinical use, with its main value in explaining decisions to patients and engaging them in the decision-making process. Suggested future improvements include tracking the outcomes of withdrawal decisions and integrating predictive models based on clinical data. Conclusions. The DST developed in this study was well-received. Its main value lies in helping pediatric rheumatologists explain their decisions to patients and parents. The top priority for further development is integrating scientific evidence on successful withdrawal decisions. Highlights: Decision support tools that provide structure to decisions based on expert opinion can increase transparency and consistency in medical decision making in the absence of clinical evidence. Data from clinical vignette studies that use an experimental design to elicit treatment preferences can be used to predict treatment decision making. A decision support tool to support biologic therapy withdrawal decisions has the most value in explaining the decision to children with nonsystemic juvenile idiopathic arthritis and their parents.
- 1 July 2025
- Published by SAGE Publications in MDM Policy & Practice
- Vol. 10 (2)
Open AccessDevelopment and Qualitative Evaluation of a Decision Support Tool for Withdrawal of Biologic Therapy in Nonsystemic Juvenile Idiopathic Arthritis
Introduction. Limited evidence guides pediatric rheumatologists on when to withdraw biologic therapy in children with juvenile idiopathic arthritis, resulting in wide variation in clinical practice. This study aimed to develop and evaluate a decision support tool (DST) based on expert opinion to support pediatric rheumatologists in making withdrawal decisions. Methods. A literature review, focus groups, interviews, and prior research informed the design of the prototype DST. Evaluation of the DST’s face validity, content validity, acceptance, and feasibility was conducted through user testing interviews and a survey among pediatric rheumatologists from the Netherlands and Canada. Findings were summarized using descriptive and qualitative content analyses. Results. The prototype DST requires input on relevant patient, disease, and treatment characteristics. Its primary output is the predicted likelihood of biologic therapy withdrawal. Pediatric rheumatologists can adjust the importance of characteristics and observe the resulting impact on withdrawal likelihood. Eleven pediatric rheumatologists participated in testing. Key themes identified included the need for 1) clear terminology to ensure consistent interpretation of model inputs, 2) concise instructions on how and when to adjust the relative importance of characteristics, and 3) practice rounds to build trust among pediatric rheumatologists in the DST’s output. Participants found the DST feasible for clinical use, with its main value in explaining decisions to patients and engaging them in the decision-making process. Suggested future improvements include tracking the outcomes of withdrawal decisions and integrating predictive models based on clinical data. Conclusions. The DST developed in this study was well-received. Its main value lies in helping pediatric rheumatologists explain their decisions to patients and parents. The top priority for further development is integrating scientific evidence on successful withdrawal decisions. Highlights: Decision support tools that provide structure to decisions based on expert opinion can increase transparency and consistency in medical decision making in the absence of clinical evidence. Data from clinical vignette studies that use an experimental design to elicit treatment preferences can be used to predict treatment decision making. A decision support tool to support biologic therapy withdrawal decisions has the most value in explaining the decision to children with nonsystemic juvenile idiopathic arthritis and their parents.
- Open Access
- 20 December 2023
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 63 (SI2) , SI143-SI151
Quantifying hospital-associated costs, and accompanying travel costs and productivity losses, before and after withdrawing TNF-α inhibitors in juvenile idiopathic arthritis
To quantify differences in hospital-associated costs, and accompanying travel costs and productivity losses, before and after withdrawing TNF-α inhibitors (TNFi) in JIA patients. This was a retrospective analysis of prospectively collected data from electronic medical records of paediatric JIA patients treated with TNFi, which were immediately discontinued, spaced (increased treatment interval) or tapered (reduced subsequent doses). Costs of hospital-associated resource use (consultations, medication, radiology procedures, laboratory testing, procedures under general anaesthesia, hospitalization) and associated travel costs and productivity losses were quantified during clinically inactive disease until TNFi withdrawal (pre-withdrawal period) and compared with costs during the first and second year after withdrawal initiation (first and second year post-withdrawal). Fifty-six patients were included of whom 26 immediately discontinued TNFi, 30 spaced and zero tapered. Mean annual costs were €9165/patient on active treatment (pre-withdrawal) and decreased significantly to €5063/patient (−44.8%) and €6569/patient (−28.3%) in the first and second year post-withdrawal, respectively (P < 0.05). Of these total annual costs, travel costs plus productivity losses were €834/patient, €1180/patient, and €1320/patient in the three periods respectively. Medication comprised 80.7%, 61.5% and 72.4% of total annual costs in the pre-withdrawal, first and second year post-withdrawal period, respectively. In the first two years after initiating withdrawal, the total annual costs were decreased compared with the pre-withdrawal period. However, cost reductions were lower in the second year compared with the first year post-withdrawal, primarily due to restarting or intensifying biologics. To support biologic withdrawal decisions, future research should assess the full long-term societal cost impacts, and include all biologics.
- 20 December 2023
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 63 (SI2) , SI143-SI151
Open AccessQuantifying hospital-associated costs, and accompanying travel costs and productivity losses, before and after withdrawing TNF-α inhibitors in juvenile idiopathic arthritis
To quantify differences in hospital-associated costs, and accompanying travel costs and productivity losses, before and after withdrawing TNF-α inhibitors (TNFi) in JIA patients. This was a retrospective analysis of prospectively collected data from electronic medical records of paediatric JIA patients treated with TNFi, which were immediately discontinued, spaced (increased treatment interval) or tapered (reduced subsequent doses). Costs of hospital-associated resource use (consultations, medication, radiology procedures, laboratory testing, procedures under general anaesthesia, hospitalization) and associated travel costs and productivity losses were quantified during clinically inactive disease until TNFi withdrawal (pre-withdrawal period) and compared with costs during the first and second year after withdrawal initiation (first and second year post-withdrawal). Fifty-six patients were included of whom 26 immediately discontinued TNFi, 30 spaced and zero tapered. Mean annual costs were €9165/patient on active treatment (pre-withdrawal) and decreased significantly to €5063/patient (−44.8%) and €6569/patient (−28.3%) in the first and second year post-withdrawal, respectively (P < 0.05). Of these total annual costs, travel costs plus productivity losses were €834/patient, €1180/patient, and €1320/patient in the three periods respectively. Medication comprised 80.7%, 61.5% and 72.4% of total annual costs in the pre-withdrawal, first and second year post-withdrawal period, respectively. In the first two years after initiating withdrawal, the total annual costs were decreased compared with the pre-withdrawal period. However, cost reductions were lower in the second year compared with the first year post-withdrawal, primarily due to restarting or intensifying biologics. To support biologic withdrawal decisions, future research should assess the full long-term societal cost impacts, and include all biologics.
- Open Access
- 11 July 2023
- Published by Springer Nature in Pediatric Rheumatology
- Vol. 21 (1) , 1-10
Withdrawing biologics in non-systemic JIA: what matters to pediatric rheumatologists?
Objective: Approximately one third of children with JIA receive biologic therapy, but evidence on biologic therapy withdrawal is lacking. This study aims to increase our understanding of whether and when pediatric rheumatologists postpone a decision to withdraw biologic therapy in children with clinically inactive non-systemic JIA. Methods: A survey containing questions about background characteristics, treatment patterns, minimum treatment time with biologic therapy, and 16 different patient vignettes, was distributed among 83 pediatric rheumatologists in Canada and the Netherlands. For each vignette, respondents were asked whether they would withdraw biologic therapy at their minimum treatment time, and if not, how long they would continue biologic therapy. Statistical analysis included descriptive statistics, logistic and interval regression analysis. Results: Thirty-three pediatric rheumatologists completed the survey (40% response rate). Pediatric rheumatologists are most likely to postpone the decision to withdraw biologic therapy when the child and/or parents express a preference for continuation (OR 6.3; p < 0.001), in case of a flare in the current treatment period (OR 3.9; p = 0.001), and in case of uveitis in the current treatment period (OR 3.9; p < 0.001). On average, biologic therapy withdrawal is initiated 6.7 months later when the child or parent prefer to continue treatment. Conclusion: Patient’s and parents' preferences were the strongest driver of a decision to postpone biologic therapy withdrawal in children with clinically inactive non-systemic JIA and prolongs treatment duration. These findings highlight the potential benefit of a tool to support pediatric rheumatologists, patients and parents in decision making, and can help inform its design.
- 11 July 2023
- Published by Springer Nature in Pediatric Rheumatology
- Vol. 21 (1) , 1-10
Open AccessWithdrawing biologics in non-systemic JIA: what matters to pediatric rheumatologists?
Objective: Approximately one third of children with JIA receive biologic therapy, but evidence on biologic therapy withdrawal is lacking. This study aims to increase our understanding of whether and when pediatric rheumatologists postpone a decision to withdraw biologic therapy in children with clinically inactive non-systemic JIA. Methods: A survey containing questions about background characteristics, treatment patterns, minimum treatment time with biologic therapy, and 16 different patient vignettes, was distributed among 83 pediatric rheumatologists in Canada and the Netherlands. For each vignette, respondents were asked whether they would withdraw biologic therapy at their minimum treatment time, and if not, how long they would continue biologic therapy. Statistical analysis included descriptive statistics, logistic and interval regression analysis. Results: Thirty-three pediatric rheumatologists completed the survey (40% response rate). Pediatric rheumatologists are most likely to postpone the decision to withdraw biologic therapy when the child and/or parents express a preference for continuation (OR 6.3; p < 0.001), in case of a flare in the current treatment period (OR 3.9; p = 0.001), and in case of uveitis in the current treatment period (OR 3.9; p < 0.001). On average, biologic therapy withdrawal is initiated 6.7 months later when the child or parent prefer to continue treatment. Conclusion: Patient’s and parents' preferences were the strongest driver of a decision to postpone biologic therapy withdrawal in children with clinically inactive non-systemic JIA and prolongs treatment duration. These findings highlight the potential benefit of a tool to support pediatric rheumatologists, patients and parents in decision making, and can help inform its design.
- Open Access
- 7 July 2022
- Published by Wiley in Arthritis Care & Research
- Vol. 74 (10) , 1585-1592
Costs of Hospital‐Associated Care for Patients With Juvenile Idiopathic Arthritis in the Dutch Health Care System
Objective: The aim of this study was to quantify costs of hospital‐associated care for juvenile idiopathic arthritis (JIA), provide insights in patient‐level variation in costs, and investigate costs over time from the moment of JIA diagnosis. Results were reported for all JIA patients in general and by subtype. Methods: This study was a single‐center, retrospective analysis of prospective data from electronic medical records of children with JIA, ages 0–18 years, between April 1, 2011 and March 31, 2019. Patient characteristics (age, sex, JIA subtype) and hospital‐based resource use (consultations, medication, radiology procedures, laboratory testing, surgeries, emergency department [ED] visits, hospital stays) were extracted and analyzed. Unit prices were obtained from Dutch reimbursement lists and pharmaceutical and hospital list prices.Results: The analysis included 691 patients. The mean total cost of hospital care was €3,784/patient/year, of which €2,103 (55.6%) was attributable to medication. Other costs involved pediatric rheumatologist visits (€633/patient/year [16.7%]), hospital stays (€439/patient/year [11.6%]), other within‐hospital specialist visits (€324/patient/year [8.6%]), radiology procedures (€119/patient/year [3.1%]), laboratory tests (€114/patient/year [3.0%]), surgeries (€46/patient/year [1.2%]), and ED visits (€6/patient/year [0.2%]). Mean annual total costs varied between JIA subtypes and between individuals and were the highest for systemic JIA (€7,772/patient/year). Over the treatment course, costs were the highest in the first month after JIA diagnosis.Conclusion: Hospital care costs of JIA vary substantially between individuals, between subtypes, and over the treatment course. The highest annual costs were for systemic JIA, primarily attributable to medication (i.e., biologics). Costs of other hospital‐associated care were comparable regardless of subtype.
- 7 July 2022
- Published by Wiley in Arthritis Care & Research
- Vol. 74 (10) , 1585-1592
Open AccessCosts of Hospital‐Associated Care for Patients With Juvenile Idiopathic Arthritis in the Dutch Health Care System
Objective: The aim of this study was to quantify costs of hospital‐associated care for juvenile idiopathic arthritis (JIA), provide insights in patient‐level variation in costs, and investigate costs over time from the moment of JIA diagnosis. Results were reported for all JIA patients in general and by subtype. Methods: This study was a single‐center, retrospective analysis of prospective data from electronic medical records of children with JIA, ages 0–18 years, between April 1, 2011 and March 31, 2019. Patient characteristics (age, sex, JIA subtype) and hospital‐based resource use (consultations, medication, radiology procedures, laboratory testing, surgeries, emergency department [ED] visits, hospital stays) were extracted and analyzed. Unit prices were obtained from Dutch reimbursement lists and pharmaceutical and hospital list prices.Results: The analysis included 691 patients. The mean total cost of hospital care was €3,784/patient/year, of which €2,103 (55.6%) was attributable to medication. Other costs involved pediatric rheumatologist visits (€633/patient/year [16.7%]), hospital stays (€439/patient/year [11.6%]), other within‐hospital specialist visits (€324/patient/year [8.6%]), radiology procedures (€119/patient/year [3.1%]), laboratory tests (€114/patient/year [3.0%]), surgeries (€46/patient/year [1.2%]), and ED visits (€6/patient/year [0.2%]). Mean annual total costs varied between JIA subtypes and between individuals and were the highest for systemic JIA (€7,772/patient/year). Over the treatment course, costs were the highest in the first month after JIA diagnosis.Conclusion: Hospital care costs of JIA vary substantially between individuals, between subtypes, and over the treatment course. The highest annual costs were for systemic JIA, primarily attributable to medication (i.e., biologics). Costs of other hospital‐associated care were comparable regardless of subtype.
- Open Access
- 18 May 2022
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 62 (SI2) , SI170-SI180
Pharmacological treatment patterns in patients with juvenile idiopathic arthritis in the Netherlands: a real-world data analysis
To investigate medication prescription patterns among children with JIA, including duration, sequence and reasons for medication discontinuation. This study is a single-centre, retrospective analysis of prospective data from the electronic medical records of JIA patients receiving systemic therapy aged 0–18 years between 1 April 2011 and 31 March 2019. Patient characteristics (age, gender, JIA subtype) and medication prescriptions were extracted and analysed using descriptive statistics, Sankey diagrams and Kaplan–Meier survival methods. Over a median of 4.2 years follow-up, the 20 different medicines analysed were prescribed as monotherapy (n = 15) or combination therapy (n = 48 unique combinations) among 236 patients. In non-systemic JIA, synthetic DMARDs were prescribed to almost all patients (99.5%), and always included MTX. In contrast, 43.9% of non-systemic JIA patients received a biologic DMARD (mostly adalimumab or etanercept), ranging from 30.9% for oligoarticular persistent ANA-positive JIA, to 90.9% for polyarticular RF-positive JIA. Among systemic JIA, 91.7% received a biologic DMARD (always including anakinra). When analysing medication prescriptions according to their class, 32.6% involved combination therapy. In 56.8% of patients, subsequent treatment lines were initiated after unsuccessful first-line treatment, resulting in 68 unique sequences. Remission was the most common reason for DMARD discontinuation (44.7%), followed by adverse events (28.9%) and ineffectiveness (22.1%). This paper reveals the complexity of pharmacological treatment in JIA, as indicated by: the variety of mono- and combination therapies prescribed, substantial variation in medication prescriptions between subtypes, most patients receiving two or more treatment lines, and the large number of unique treatment sequences.
- 18 May 2022
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 62 (SI2) , SI170-SI180
Open AccessPharmacological treatment patterns in patients with juvenile idiopathic arthritis in the Netherlands: a real-world data analysis
To investigate medication prescription patterns among children with JIA, including duration, sequence and reasons for medication discontinuation. This study is a single-centre, retrospective analysis of prospective data from the electronic medical records of JIA patients receiving systemic therapy aged 0–18 years between 1 April 2011 and 31 March 2019. Patient characteristics (age, gender, JIA subtype) and medication prescriptions were extracted and analysed using descriptive statistics, Sankey diagrams and Kaplan–Meier survival methods. Over a median of 4.2 years follow-up, the 20 different medicines analysed were prescribed as monotherapy (n = 15) or combination therapy (n = 48 unique combinations) among 236 patients. In non-systemic JIA, synthetic DMARDs were prescribed to almost all patients (99.5%), and always included MTX. In contrast, 43.9% of non-systemic JIA patients received a biologic DMARD (mostly adalimumab or etanercept), ranging from 30.9% for oligoarticular persistent ANA-positive JIA, to 90.9% for polyarticular RF-positive JIA. Among systemic JIA, 91.7% received a biologic DMARD (always including anakinra). When analysing medication prescriptions according to their class, 32.6% involved combination therapy. In 56.8% of patients, subsequent treatment lines were initiated after unsuccessful first-line treatment, resulting in 68 unique sequences. Remission was the most common reason for DMARD discontinuation (44.7%), followed by adverse events (28.9%) and ineffectiveness (22.1%). This paper reveals the complexity of pharmacological treatment in JIA, as indicated by: the variety of mono- and combination therapies prescribed, substantial variation in medication prescriptions between subtypes, most patients receiving two or more treatment lines, and the large number of unique treatment sequences.
- Open Access
- 21 October 2021
- Published by Springer Nature in Rheumatology International
- Vol. 42 (9) , 1565-1572
Monitoring of rheumatoid arthritis: a patient survey on disease insight and possible added value of an innovative inflammation monitoring device
To enable patients with rheumatoid arthritis (RA) and their healthcare professionals to choose the optimal treatment, it is crucial to accurately assess the current state of inflammatory activity. The objectives of this study were to (1) investigate the perspective of RA patients on their insight into the current status of their disease, and to (2) investigate the patients’ perspective on the possible added value of a monitoring device based on optical spectral transmission—called the HandScan—that measures the location and severity of joint inflammation. A survey was distributed online among patients with RA in the Netherlands. Four-hundred and eight patients with RA completed the survey. Of these, 298 (73%) felt they have sufficient insight into their current disease status. Most respondents perceived either a large (n = 242; 59%) or small (n = 148; 36%) added value of the HandScan in their monitoring process, mostly because the device provides additional knowledge on the presence of inflammation. This perceived added value was higher for respondents experienced with the device (n = 46; p = .04). Respondents preferred monitoring with the device on every (n = 192; 47%) or most (n = 171; 42%) visits to the outpatient clinic, or even more often than on every visit (n = 17; 4%). Monitoring RA using an optical spectral transmission device is seen by patients as a possibly valuable addition to the monitoring process of inflammatory activity during visits to an outpatient clinic. Their main reason was that the device can increase insight into their current disease status. More insight may support patients in discussing treatment options with their rheumatologist.
- 21 October 2021
- Published by Springer Nature in Rheumatology International
- Vol. 42 (9) , 1565-1572
Open AccessMonitoring of rheumatoid arthritis: a patient survey on disease insight and possible added value of an innovative inflammation monitoring device
To enable patients with rheumatoid arthritis (RA) and their healthcare professionals to choose the optimal treatment, it is crucial to accurately assess the current state of inflammatory activity. The objectives of this study were to (1) investigate the perspective of RA patients on their insight into the current status of their disease, and to (2) investigate the patients’ perspective on the possible added value of a monitoring device based on optical spectral transmission—called the HandScan—that measures the location and severity of joint inflammation. A survey was distributed online among patients with RA in the Netherlands. Four-hundred and eight patients with RA completed the survey. Of these, 298 (73%) felt they have sufficient insight into their current disease status. Most respondents perceived either a large (n = 242; 59%) or small (n = 148; 36%) added value of the HandScan in their monitoring process, mostly because the device provides additional knowledge on the presence of inflammation. This perceived added value was higher for respondents experienced with the device (n = 46; p = .04). Respondents preferred monitoring with the device on every (n = 192; 47%) or most (n = 171; 42%) visits to the outpatient clinic, or even more often than on every visit (n = 17; 4%). Monitoring RA using an optical spectral transmission device is seen by patients as a possibly valuable addition to the monitoring process of inflammatory activity during visits to an outpatient clinic. Their main reason was that the device can increase insight into their current disease status. More insight may support patients in discussing treatment options with their rheumatologist.
- Open Access
- 29 December 2020
- Published by Taylor & Francis in Expert Review of Pharmacoeconomics & Outcomes Research
- Vol. 21 (5) , 975-984
Costs of medication use among patients with juvenile idiopathic arthritis in the Dutch healthcare system
Background: This study aims to quantify medication costs in juvenile idiopathic arthritis (JIA), based on subtype. Research design and methods: This study is a single-center, retrospective analysis of prospective data from electronic medical records of JIA patients, aged 0-18 years between April 1, 2011 and March 31, 2019. Patient characteristics (age, gender, subtype) and medication use were extracted. Medication use and costs were reported as: 1) mean total annual costs; 2) between-patient heterogeneity in these costs; 3) duration of medication use; and, 4) costs over the treatment course. Results: The analysis included 691 patients. Mean total medication costs were €2,103/patient/year, including €1,930/patient/year (91.8%) spent on biologicals. Costs varied considerably between subtypes, with polyarticular rheumatoid-factor positive and systemic JIA patients having the highest mean costs (€5,020/patient/year and €4,790/patient/year, respectively). Mean annual medication costs over the patient’s treatment course ranged from <€1,000/year (71.1% of patients) to >€11,000/year (2.5% of patients). Etanercept and adalimumab were the most commonly used biologicals. Cost fluctuations over the treatment course were primarily attributable to biological use. Conclusions: Polyarticular rheumatoid-factor positive and systemic JIA patients had the highest mean total annual medication costs, primarily attributable to biologicals. Costs varied considerably between subtypes, individuals, and over the treatment course.
- 29 December 2020
- Published by Taylor & Francis in Expert Review of Pharmacoeconomics & Outcomes Research
- Vol. 21 (5) , 975-984
Open AccessCosts of medication use among patients with juvenile idiopathic arthritis in the Dutch healthcare system
Background: This study aims to quantify medication costs in juvenile idiopathic arthritis (JIA), based on subtype. Research design and methods: This study is a single-center, retrospective analysis of prospective data from electronic medical records of JIA patients, aged 0-18 years between April 1, 2011 and March 31, 2019. Patient characteristics (age, gender, subtype) and medication use were extracted. Medication use and costs were reported as: 1) mean total annual costs; 2) between-patient heterogeneity in these costs; 3) duration of medication use; and, 4) costs over the treatment course. Results: The analysis included 691 patients. Mean total medication costs were €2,103/patient/year, including €1,930/patient/year (91.8%) spent on biologicals. Costs varied considerably between subtypes, with polyarticular rheumatoid-factor positive and systemic JIA patients having the highest mean costs (€5,020/patient/year and €4,790/patient/year, respectively). Mean annual medication costs over the patient’s treatment course ranged from <€1,000/year (71.1% of patients) to >€11,000/year (2.5% of patients). Etanercept and adalimumab were the most commonly used biologicals. Cost fluctuations over the treatment course were primarily attributable to biological use. Conclusions: Polyarticular rheumatoid-factor positive and systemic JIA patients had the highest mean total annual medication costs, primarily attributable to biologicals. Costs varied considerably between subtypes, individuals, and over the treatment course.